.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,722,650

« Back to Dashboard
Patent 8,722,650 protects SOLODYN and is included in one NDA. There have been four Paragraph IV challenges on Solodyn. There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 8,722,650

Title:Extended-release minocycline dosage forms
Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Scottsdale, AZ), Newhard; Steven B. (Scottsdale, AZ), Watt; David (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:12/861,424
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-008Aug 27, 2010RXNo8,722,650► subscribe TREATMENT OF ACNE
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-007Aug 27, 2010RXNo8,722,650► subscribe TREATMENT OF ACNE
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-006Aug 27, 2010RXNo8,722,650► subscribe TREATMENT OF ACNE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,722,650

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,804Minocycline oral dosage forms for the treatment of acne► subscribe
7,544,373Minocycline oral dosage forms for the treatment of acne► subscribe
9,192,615Method for the treatment of acne and certain dosage forms thereof► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,722,650

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101208097► subscribe
European Patent Office1898925► subscribe
Israel188331► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc